Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Nov 10, 2024 12:04pm
109 Views
Post# 36305432

RE:RE:RE:Hi all,

RE:RE:RE:Hi all, I think many would be pleased to see Onc be bought out by a Roche.
They certainly know Onc/ Palareorep clinical potential.
They have been working alongside , with ONC for a very long time.
Again, endorsement from CGAR to $5million grant.FDA favourable directions,
including fast track designation for MBc & panc cancer.
With discussions of potential accelerated approval.
All "value added" accomplishments.
As notable has posted, many junior biotechs, have been bought out for $billions, offering much less than Onc has to offer.
My advice , not changed.
price is silly low right now. If you belive in the science, time to buy.
Certainly not time to sell.
im holding , until they succeed or fail.
right now, ALL the recent news updates are very positive.
They need to spin that into a deal.
Roche a great option.



<< Previous
Bullboard Posts
Next >>